Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).

Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE.

Prog Med Chem. 2018;57(1):87-111. doi: 10.1016/bs.pmch.2017.12.002. Epub 2018 Mar 7.

PMID:
29680151
2.

New findings in pharmacogenetics of schizophrenia.

Zai CC, Tiwari AK, Zai GC, Maes MS, Kennedy JL.

Curr Opin Psychiatry. 2018 May;31(3):200-212. doi: 10.1097/YCO.0000000000000417.

PMID:
29528898
3.

Deuterium Tetrabenazine for Tardive Dyskinesia.

Cummings MA, Proctor GJ, Stahl SM.

Clin Schizophr Relat Psychoses. 2018 Jan;11(4):214-220. doi: 10.3371/CSRP.CUPR.010318. Review.

PMID:
29341821
4.

Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.

Purves-Tyson TD, Owens SJ, Rothmond DA, Halliday GM, Double KL, Stevens J, McCrossin T, Shannon Weickert C.

Transl Psychiatry. 2017 Jan 17;7(1):e1003. doi: 10.1038/tp.2016.257.

5.

Pharmacogenetics of tardive dyskinesia: an updated review of the literature.

Lanning RK, Zai CC, Müller DJ.

Pharmacogenomics. 2016 Aug;17(12):1339-51. doi: 10.2217/pgs.16.26. Epub 2016 Jul 29. Review.

PMID:
27469238
6.

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.

Mas S, Gassó P, Lafuente A, Bioque M, Lobo A, Gonzàlez-Pinto A, Olmeda MS, Corripio I, Llerena A, Cabrera B, Saiz-Ruiz J, Bernardo M; PEPs GROUP.

Pharmacogenomics J. 2016 Oct;16(5):439-45. doi: 10.1038/tpj.2016.44. Epub 2016 Jun 7.

PMID:
27272046
7.

Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.

Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL.

J Psychiatr Res. 2013 Nov;47(11):1760-5. doi: 10.1016/j.jpsychires.2013.07.025. Epub 2013 Sep 6.

PMID:
24018103
8.

Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort.

Kukshal P, Kodavali VC, Srivastava V, Wood J, McClain L, Bhatia T, Bhagwat AM, Deshpande SN, Nimgaonkar VL, Thelma BK.

J Psychiatr Res. 2013 Nov;47(11):1615-22. doi: 10.1016/j.jpsychires.2013.07.007. Epub 2013 Aug 8.

9.
10.

Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal region of genetic animal model of schizophrenia.

Iritani S, Sekiguchi H, Habuchi C, Hikita T, Taya S, Kaibuchi K, Ozaki N.

Synapse. 2010 Dec;64(12):948-53. doi: 10.1002/syn.20846.

PMID:
20815037
11.

Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders.

Lohoff FW.

Methods Mol Biol. 2010;637:165-80. doi: 10.1007/978-1-60761-700-6_9.

PMID:
20419435
12.

An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes.

Chu TT, Liu Y.

J Hum Genet. 2010 May;55(5):285-92. doi: 10.1038/jhg.2010.24. Epub 2010 Mar 26.

PMID:
20339380
13.

Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals.

Qi Z, Miller GW, Voit EO.

Synapse. 2009 Dec;63(12):1133-42. doi: 10.1002/syn.20686.

14.

Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission.

Bouvrais-Veret C, Weiss S, Hanoun N, Andrieux A, Schweitzer A, Job D, Hamon M, Giros B, Martres MP.

J Neurochem. 2008 Feb;104(3):745-56. doi: 10.1111/j.1471-4159.2007.05025.x.

15.

A network of dopaminergic gene variations implicated as risk factors for schizophrenia.

Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, Mansour H, Chowdari KV, Milanova V, Wood J, McClain L, Prasad K, Shirts B, Zhang J, O'Donovan MC, Owen MJ, Devlin B, Nimgaonkar VL.

Hum Mol Genet. 2008 Mar 1;17(5):747-58. Epub 2007 Nov 27.

16.

Identification of two risk haplotypes for schizophrenia and bipolar disorder in the synaptic vesicle monoamine transporter gene (SVMT).

Gutiérrez B, Rosa A, Papiol S, Arrufat FJ, Catalán R, Salgado P, Peralta V, Cuesta MJ, Fañanás L.

Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):502-7.

PMID:
17427184
17.

Support for association of the A277C single nucleotide polymorphism in human vesicular monoamine transporter 1 gene with schizophrenia.

Chen SF, Chen CH, Chen JY, Wang YC, Lai IC, Liou YJ, Liao DL.

Schizophr Res. 2007 Feb;90(1-3):363-5. Epub 2007 Jan 16. No abstract available.

PMID:
17223313
18.

Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin.

Clinton SM, Ibrahim HM, Frey KA, Davis KL, Haroutunian V, Meador-Woodruff JH.

Am J Psychiatry. 2005 Oct;162(10):1859-71.

PMID:
16199832
19.

Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.

Zucker M, Valevski A, Weizman A, Rehavi M.

Eur Neuropsychopharmacol. 2002 Aug;12(4):343-7.

PMID:
12126874
20.

Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism.

Mooslehner KA, Chan PM, Xu W, Liu L, Smadja C, Humby T, Allen ND, Wilkinson LS, Emson PC.

Mol Cell Biol. 2001 Aug;21(16):5321-31.

Supplemental Content

Loading ...
Support Center